Accession Number : ADA188442
Title : Synthesis of Improved Antileishmanial and Antitrypanosomal Drugs.
Descriptive Note : Final rept. 1 Oct 77-31 Mar 84; Annual rept. 1 Jan-31 Mar 84,
Corporate Author : ASH STEVENS INC DETROIT MI
Personal Author(s) : Markovac, Anica ; LaMontagne, Maurice P ; Dagli, Dinesh J ; Wu, Geng-Shuen ; Khan, M S
PDF Url : ADA188442
Report Date : Aug 1984
Pagination or Media Count : 45
Abstract : The present contract was intended to provide synthesis support for the research effort against leishmaniasis and trypanosomiasis. The objective was to acquire superior drugs relative to current antileishmanial and antitrypanosomal experimental and clinical drugs. The recognized group of four diseases caused by protozoal parasites (haemoflagellates) belong to the family Trypanosomatidae and the genus Leishmania: Leishmania donovani, L. brasiliensis, L. tropica and L. mexicana. The army is extensively involved in both the biological and therapeutic aspects of the diseases generated by the first three of these parasites. The most lethal form of the disease is visceral leishmaniasis (kala-azar) which is generated by L. donovani and is fatal in 98% of untreated cases. To evaluate new candidate drugs, the Army provides a test screen developed by W.L. Hanson based on L. donovani in the golden hamster in which the drug is administered IM or SC and, if warranted, PO. The second genus of the family Trypanosomatidae is the genus Trypanosoma. The Army provides a test system for T. rhodesiense (both SC and PO) in the mouse and the more refractory T. cruzi in the mouse and the feedback of results from the T. rhodesiense test is quite rapid. Data indicate that new leads have been developed against L. donovani and T. rhodesiense. Keywords: Chemotherapy, antiparasitic drugs.
Descriptors : *ANTIPARASITIC DRUGS, *LEISHMANIASIS, *TRYPANOSOMIASIS, CHEMOTHERAPY, FEEDBACK, LEISHMANIA, MICE, TRYPANOSOMA, PARASITIC DISEASES, DISEASES, DRUGS
Subject Categories : Pharmacology
Distribution Statement : APPROVED FOR PUBLIC RELEASE